I honestly do not really understand this second news today either. It seems mostly like a repetition of the news from Thursday. Except maybe the explicit info that the announced deal is limited to China and GNBT plans to profit first financially from and then intellectually from this deal. What I like is that they will base the clinical trials in the US on the results of the preclinical studies from China. This is really good news to me.